Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 5/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.37 |
| ▸ | KLK7 | P49862 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 5/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16739977 | 0.83 | KDM4E (0.41) | KDM4EALDH1A1HPGDGAARAB9A | |
| SCHEMBL18100941 | 0.80 | MAPT (0.50) | KDM4EALDH1A1HPGDGAARAB9A | |
| SCHEMBL16740008 | 0.78 | HSD17B10 (0.41) | KDM4EALDH1A1HPGDGAARAB9A | |
| SCHEMBL16747972 | 0.77 | PKM (0.53) | KDM4EALDH1A1HPGDGAARAB9A | |
| SCHEMBL16748003 | 0.73 | ALDH1A1 (0.43) | KDM4EALDH1A1HPGDGAARAB9A | |
| SCHEMBL16739626 | 0.72 | ROCK1 (0.43) | KDM4EALDH1A1HPGDGAARAB9A | |
| SCHEMBL16739848 | 0.69 | ALDH1A1 (0.50) | KDM4EALDH1A1HPGDGAARAB9A | |
| SCHEMBL16740003 | 0.68 | PKM (0.53) | KDM4EALDH1A1HPGDGAARAB9A | |
| SCHEMBL13377062 | 0.65 | KDM4E (0.55) | KDM4EALDH1A1HPGDGAARAB9A | |
| SCHEMBL29893700 | 0.65 | KLK7 (0.41) | KDM4EALDH1A1HPGDGAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10584115-B2 | Substituted pyridine and pyrazine BMI-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2020-03-10 | — | — | US | disclosed |
| US-20160280685-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-09-29 | — | — | US | disclosed |
| US-20160280685-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-09-29 | — | — | US | disclosed |
| EP-3071553-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC Therapeutics, Inc. (US) | 2016-09-28 | — | — | EP | disclosed |
| WO-2015076800-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. (US) | 2015-05-28 | — | — | WO | disclosed |
| WO-2015076800-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. (US) | 2015-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280685-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | BMI1, BAZ2A, BAZ2B | KDM4E 102/4885ALDH1A1 1727/4885HPGD 4481/4885 |
| US-10584115-B2 | Substituted pyridine and pyrazine BMI-1 inhibitors | BMI1, BAZ2A, BAZ2B | KDM4E 102/4885ALDH1A1 1727/4885HPGD 4481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.